The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP. The specific objectives are:~To characterize and demonstrate the longitudinal progression of tau deposition in vivo in participants with PSP.~To determine optimal PET analysis parameters for [18F]APN-1607 quantification.~To characterize the stability of tau deposition in vivo over time in healthy volunteers (HVs).~To evaluate consistency of [18F]APN-1607 quantification in characterizing tau deposition.
The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.